Physician profile
Michael Rawlins
NPI 1225199441
$49,916.17
in general payments reported to CMS, 2019-2025
20 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,791 · 2021: $12K · 2022: $12K · 2023: $3,185 · 2024: $894 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Travel and Lodging: $1,934 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.34 |
| Travel and Lodging | $1,933.70 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,722.79 | 2021-2025 | Da Vinci Surgical System |
| Ethicon INC. | $11,786.79 | 2019-2022 | |
| Medical Device Business Services, INC. | $9,490.09 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $5,742.08 | 2019-2024 | Gore Bio-A Tissue Reinforcement, Gore Enform Preperitoneal Biomaterial, Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Pacira Pharmaceuticals Incorporated | $3,404.95 | 2019 | |
| Ethicon US, LLC | $2,415.56 | 2019-2024 | Echelon Endopath |
| Medtronic, INC. | $597.19 | 2021-2022 | |
| Covidien Lp | $141.27 | 2020 | |
| Ethicon Endo-Surgery INC. | $133.08 | 2025 | Echelon; Endopath |
| Phathom Pharmaceuticals, INC. | $119.68 | 2024 | Voquezna |
| Novo Nordisk INC | $89.99 | 2024-2025 | Wegovy |
| Intra-Sana Laboratories | $58.77 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Tela Bio, INC. | $40.10 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $38.05 | 2024 | Phasix Mesh |
| Smith+Nephew, INC. | $27.91 | 2025 | Grafix Pl, Stravix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanara Medtech INC. | $22.60 | 2025 | Celleraterx |
| Lilly USA, LLC | $22.25 | 2025 | Zepbound |
| Astellas Pharma US INC | $21.93 | 2019 | |
| Aroa Biosurgery Incorporated | $21.40 | 2025 | |
| Teleflex LLC | $19.69 | 2025 | Titan Sgs Bailout Chuck |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rawlins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.